Provided by Tiger Trade Technology Pte. Ltd.

Enlivex Therapeutics Ltd.

1.47
-0.0300-2.00%
Post-market: 1.510.0400+2.72%19:58 EDT
Volume:157.53K
Turnover:231.16K
Market Cap:25.70M
PE:0.00
High:1.52
Open:1.49
Low:1.39
Close:1.50
52wk High:27.15
52wk Low:1.39
Shares:17.49M
Float Shares:5.32M
Volume Ratio:0.64
T/O Rate:2.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):382.20
EPS(LYR):382.20
ROE:126.17%
ROA:-0.80%
PB:0.01
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Enlivex Therapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
- -
Office Location:
14 Einstein Street,Ness Ziona,Israel
Zip Code:
7403618
Fax:
- -
Introduction:
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Directors

Name
Position
Roger Pomerantz
Director and Vice Chairman of the Board
Shai Novik
Executive Chairman of the Board
Abraham Havron
Director
Gili Hart
Director
Matteo Renzi
Director

Shareholders

Name
Position
Oren Hershkovits
Chief Executive Officer
Shachar Shlosberger
Chief Financial Officer
Einat Galamidi
Chief Medical Officer
Shai Novik
Executive Chairman of the Board